Compare CRDF & IBEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRDF | IBEX |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 130.7M | 489.1M |
| IPO Year | 2012 | 2017 |
| Metric | CRDF | IBEX |
|---|---|---|
| Price | $1.83 | $28.68 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 2 |
| Target Price | $9.63 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 686.2K | 107.8K |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 27.37 | ★ 28.26 |
| EPS | N/A | ★ 1.65 |
| Revenue | $365,993.00 | ★ $558,273,000.00 |
| Revenue This Year | N/A | $13.14 |
| Revenue Next Year | N/A | $5.67 |
| P/E Ratio | ★ N/A | $17.39 |
| Revenue Growth | ★ 49.61 | 9.77 |
| 52 Week Low | $1.48 | $21.64 |
| 52 Week High | $4.56 | $42.99 |
| Indicator | CRDF | IBEX |
|---|---|---|
| Relative Strength Index (RSI) | 45.54 | 35.66 |
| Support Level | $1.51 | $27.70 |
| Resistance Level | $2.41 | $29.10 |
| Average True Range (ATR) | 0.14 | 0.88 |
| MACD | 0.03 | 0.25 |
| Stochastic Oscillator | 55.00 | 39.81 |
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
IBEX Ltd delivers innovative business process outsourcing (BPO), smart digital marketing, online acquisition technology, and end-to-end customer engagement solutions to help companies acquire, engage, and retain valuable customers. It is an end-to-end provider of technology-enabled customer lifecycle experience (CLX) solutions to optimize customer acquisition, engagement, expansion, and experience for its clients. IBEX operates through the Business process outsourcing segment. Its services cover three areas: Digital and omni-channel Customer Experience (ibex Connect), Digital Marketing and E-Commerce (ibex Digital) and Digital CX surveys and analytics (ibex CX). It caters to a broad range of industries, such as telecommunications, cable, financial services, and healthcare.